159 related articles for article (PubMed ID: 2459512)
1. Age and the platelet serotonin vasoconstrictor axis in essential hypertension.
Amstein R; Fetkovska N; Lüscher TF; Kiowski W; Bühler FR
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S35-40. PubMed ID: 2459512
[TBL] [Abstract][Full Text] [Related]
2. Serotonin and preactivated platelets in essential hypertension.
Bühler FR; Amstein R; Fetkovska N
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S32-4. PubMed ID: 2446066
[TBL] [Abstract][Full Text] [Related]
3. Platelet serotonin-LDL interaction in essential hypertension.
Amstein R; Fetkovska N; Bühler FR
J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S35-40. PubMed ID: 1717771
[TBL] [Abstract][Full Text] [Related]
4. Age, platelet serotonin kinetics and 5HT2-receptor blockade in essential hypertension.
Amstein R; Fetkovska N; Bühler FR
J Hum Hypertens; 1990 Aug; 4(4):441-4. PubMed ID: 2258891
[TBL] [Abstract][Full Text] [Related]
5. [In vivo platelet activation in mild arterial hypertension].
Guicheney P; Baudouin-Legros M; Meyer P
Arch Mal Coeur Vaiss; 1987 Jun; 80(6):808-11. PubMed ID: 2959230
[TBL] [Abstract][Full Text] [Related]
6. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
Amstein R; Fetkovska N; Pletscher A; Bühler FR
J Hypertens; 1989 Apr; 7(4):255-60. PubMed ID: 2723427
[TBL] [Abstract][Full Text] [Related]
7. 5-hydroxytryptamine and vascular disease.
Vanhoutte PM
Fed Proc; 1983 Feb; 42(2):233-7. PubMed ID: 6822294
[TBL] [Abstract][Full Text] [Related]
8. Serotonin, hypertension and vascular disease.
Vanhoutte PM
Neth J Med; 1991 Feb; 38(1-2):35-42. PubMed ID: 2030808
[TBL] [Abstract][Full Text] [Related]
9. Amplification of 5-hydroxytryptamine-induced contractile responses via 5-hydroxytryptamine receptors and alpha-adrenoceptors in dog mesenteric artery and vein.
Shimamoto H; Shimamoto Y; Kwan CY; Daniel EE
J Pharmacol Exp Ther; 1994 Feb; 268(2):779-84. PubMed ID: 8113990
[TBL] [Abstract][Full Text] [Related]
10. Age and 5HT 2-receptor blockade with ketanserin in essential hypertension.
Bühler FR; Amstein R
Rev Port Cardiol; 1989 Sep; 8(9):621-4. PubMed ID: 2698721
[TBL] [Abstract][Full Text] [Related]
11. Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets.
Jagroop IA; Mikhailidis DP
J Hum Hypertens; 2001 Mar; 15(3):203-7. PubMed ID: 11317206
[TBL] [Abstract][Full Text] [Related]
12. Serotonergic type-2 (5-HT2) antagonists: a novel class of cardiovascular drugs.
Robertson JI
J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S48-53. PubMed ID: 1717773
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive properties of ketanserin (R 41 468).
Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
[TBL] [Abstract][Full Text] [Related]
14. 5-Hydroxytryptamine(2B) receptor function is enhanced in the N(omega)-nitro-L-arginine hypertensive rat.
Russell A; Banes A; Berlin H; Fink GD; Watts SW
J Pharmacol Exp Ther; 2002 Oct; 303(1):179-87. PubMed ID: 12235249
[TBL] [Abstract][Full Text] [Related]
15. Serotonin and the blood vessel wall.
Vanhoutte PM; Lüscher TF
J Hypertens Suppl; 1986 Apr; 4(1):S29-35. PubMed ID: 2939211
[TBL] [Abstract][Full Text] [Related]
16. Serotonin, 5-HT2 receptors, and their blockade by naftidrofuryl: a targeted therapy of vascular diseases.
Wiernsperger NF
J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S37-43. PubMed ID: 7517475
[TBL] [Abstract][Full Text] [Related]
17. 5-HT receptors mediating external carotid vasoconstriction in vagosympathectomized dogs.
Villalón CM; Centurión D; Sánchez-López A; De Vries P; Saxena P
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1057-67. PubMed ID: 11216445
[TBL] [Abstract][Full Text] [Related]
18. Hypotensive and antiaggregative effects of eugenosedin-B with serotonin and alpha/beta-adrenoceptor antagonistic activities in rats and human platelets.
Shen KP; Chu LW; Hsieh SL; An LM; Chen IJ; Wu BN
J Cardiovasc Pharmacol; 2008 Feb; 51(2):154-61. PubMed ID: 18287883
[TBL] [Abstract][Full Text] [Related]
19. Vascular effects of serotonin and ischemia.
Vanhoutte PM
J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S15-9. PubMed ID: 1369711
[TBL] [Abstract][Full Text] [Related]
20. Serotonin as a factor involved in pathophysiology of thromboangiitis obliterans.
Pietraszek MH; Choudhury NA; Baba S; Sakaguchi S; Hachiya T; Urano T; Takada Y; Takada A
Int Angiol; 1993 Mar; 12(1):9-12. PubMed ID: 8376917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
